The 21 most recent market catalysts affecting $SRRK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $77
Truist Securities analyst Srikripa Devarakonda reiterated a 'Buy' rating for Scholar Rock Holding (SRRK) and raised the price target by a single dollar, from $76 to $77. This actio…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $70
JP Morgan's analyst Tessa Romero maintained an 'Overweight' rating on Scholar Rock Holding (SRRK) and raised the price target from $63 to $70. This action signals continued confide…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Group Maintains Outperform on Scholar Rock Holding, Raises Price Target to $72
Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on Scholar Rock Holding (SRRK) and raised the price target from $65 to $72. This analyst upgrade signals i…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 60
Piper Sandler Maintains Overweight on Scholar Rock Holding, Raises Price Target to $75
Piper Sandler analyst Allison Bratzel maintained an 'Overweight' rating on Scholar Rock Holding (SRRK) and raised the price target from $60 to $75. This upgrade in price target sug…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 55
Jefferies Maintains Buy on Scholar Rock Holding, Raises Price Target to $65
Jefferies analyst Amy Li maintained a 'Buy' rating on Scholar Rock Holding (SRRK) and raised the price target from $57 to $65. This upgrade in price target suggests increased optim…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $70
Wedbush analyst David Nierengarten maintained an 'Outperform' rating on Scholar Rock Holding (SRRK) and raised the price target from $64 to $70. This action indicates a positive ou…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 60
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $70
HC Wainwright & Co. analyst Andres Y. Maldonado maintained a 'Buy' rating on Scholar Rock Holding (SRRK) and raised the price target from $65 to $70. This action signals increased …
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 55
Raymond James Maintains Strong Buy on Scholar Rock Holding, Raises Price Target to $72
Raymond James analyst Gary Nachman has reaffirmed a 'Strong Buy' rating for Scholar Rock Holding (SRRK) and raised the price target from $65 to $72. This action signals increased a…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 55
BMO Capital Maintains Outperform on Scholar Rock Holding, Raises Price Target to $84
BMO Capital's analyst Etzer Darout reiterated an 'Outperform' rating for Scholar Rock Holding and raised the price target from $76 to $84. This action signals increased confidence …
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 65
Truist Securities Reiterates Buy on Scholar Rock Holding, Raises Price Target to $76
Truist Securities analyst Srikripa Devarakonda has reaffirmed a 'Buy' rating for Scholar Rock Holding and raised the price target from $55 to $76. This action signals a strong vote…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $74
Citigroup analyst Geoff Meacham has maintained a 'Buy' rating on Scholar Rock Holding (SRRK) and raised the price target from $60 to $74. This indicates a strengthened conviction i…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 95
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
Scholar Rock (SRRK) received FDA approval for ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy (SMA), marking a 'defining moment' for the company. This is the first muscle-t…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 55
Scholar Rock Exec Says Its First Drug To Target Muscle Loss In Spinal Muscular Atrophy Has A Wholesale Acquisition Cost Of $11,659 For A Single Use Vial; Exec Says Co Expects The Annual Net Cost In The U.S. For A Typical Patient To Be ~$310,000
The filing indicates that a Scholar Rock executive, during a conference call, revealed the wholesale acquisition cost (WAC) of their new SMA drug to be $11,659 per vial and the exp…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target
The filing indicates that HC Wainwright & Co. analyst Andres Y. Maldonado has reiterated a 'Buy' rating and maintained a $65 price target for Scholar Rock Holding. This action sign…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 75
Scholar Rock Receives FDA's Fast Track And Orphan Drug Designations For Apitegromab To Treat Facioscapulohumeral Muscular Dystrophy
Scholar Rock (SRRK) announced that its investigational drug, apitegromab, received both Fast Track and Orphan Drug designations from the FDA for the treatment of Facioscapulohumera…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63
JP Morgan's analyst Tessa Romero has maintained an 'Overweight' rating on Scholar Rock Holding and raised the price target from $56 to $63. This indicates a strengthened positive o…
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target
The filing indicates that HC Wainwright & Co. analyst Andres Y. Maldonado has reaffirmed a 'Buy' rating and a $65 price target for Scholar Rock Holding. This action signals continu…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $60
Citigroup analyst Geoff Meacham maintained a 'Buy' rating on Scholar Rock Holding (SRRK) and raised the price target from $58 to $60. This action indicates that a prominent analyst…
Aug 7, 2026
Corporate Catalyst
Neutral
Impact 75
Scholar Rock Removes Catalent Indiana From Apitegromab BLA After FDA OAI Classification; FDA Review Remains On Track for Sept. 30 PDUFA Using Second Fill-Finish Site
Scholar Rock announced that it is removing Catalent Indiana as a fill-finish facility from its apitegromab BLA after Catalent received an Official Action Indicated (OAI) classifica…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Scholar Rock Holding shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for Scholar Rock Holding. Better-than-expected financial results typically lead to increased investor confidence, driving …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492M
Scholar Rock Holding (SRRK) announced Q2 losses of $(0.84) per share, which was better than the analyst consensus estimate of $(0.85). This represents a 1.18% beat and a 14.29% imp…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.